Fortrea Unveils Fortrea Intelligent Technology™ to Help Sponsors and Sites Run Smarter, More Integrated Trials

Rhea-AI Summary

Fortrea (Nasdaq: FTRE) unveiled Fortrea Intelligent Technology™ (FIT) on April 7, 2026, a suite of AI-enhanced solutions built on the Xcellerate® platform to automate workflows, streamline oversight and deliver near-real-time, role-based insights for sponsors, investigator sites and study teams.

FIT is arranged into three pillars — Lifecycle, Foresight and Companion — and supports clinical pharmacology, clinical development and medical device programs across full-service, functional service and select SaaS deployments.

News Market Reaction – FTRE

+5.55%

10 alerts

+5.55% Session close to close

+21.0% Peak in 24 hr 25 min

$971.47M Market Cap

0.4x Rel. Volume

In the Apr 7 session, FTRE gained 5.55%, reflecting a notable positive market reaction. Argus tracked a peak move of +21.0% during that session. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +5.5% in the session following this news. A strong positive reaction aligns with For...

Analysis

The stock moved +5.5% in the session following this news. A strong positive reaction aligns with Fortrea’s emphasis on technology-enabled clinical trial operations. The launch of Fortrea Intelligent Technology™, anchored by the enhanced Xcellerate® platform, builds on prior strategic steps like executive expansion and recent RSU-based hiring. Investors evaluating such a move would typically weigh whether the AI- and machine learning–driven tools meaningfully differentiate Fortrea’s CRO offering and help leverage its existing $7,728.0M backlog from earlier disclosures.

Historical Context

5 past events · Latest: Mar 10 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 10	Inducement RSU grants	Neutral	+5.3%	Granted 130,000 RSUs to four new hires under inducement award plan.
Feb 26	Earnings and guidance	Negative	+4.5%	Reported 2025 revenue, sizable GAAP net loss with goodwill impairment and 2026 guidance.
Feb 17	Executive expansion	Positive	-0.9%	Appointed new CMO focus and President of Clinical Pharmacology Services to deepen capabilities.
Jan 29	Earnings date set	Neutral	+1.9%	Announced timing and call details for Q4 and full-year 2025 results release.
Jan 09	Conference schedule	Neutral	-0.3%	Updated presentation time for J.P. Morgan Healthcare Conference with webcast access.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news often saw positive or neutral items accompanied by modest gains, while the major earnings update with large GAAP losses drew a positive reaction, indicating occasional divergence between fundamentals and price.

Recent Company History

Over the last six months, Fortrea has reported key milestones including inducement RSU grants on Mar 10, 2026, 2025 earnings and 2026 guidance on Feb 26, 2026, and executive team expansion on Feb 17, 2026. Earlier, it set the Q4/FY25 earnings date and adjusted its J.P. Morgan conference presentation time. Against that backdrop, today’s launch of Fortrea Intelligent Technology™ extends the strategic focus on operational capabilities and technology-enabled clinical trial delivery rather than capital markets actions.

Key Terms

clinical pharmacology, risk-based quality management (rbqm), central monitoring, eTMF, +3 more

7 terms

clinical pharmacology medical

"applications for biopharma and biotech customers across clinical pharmacology, clinical development"

Clinical pharmacology is the study of how medicines behave in humans — how they are absorbed, distributed, metabolized and eliminated, and what effects and side effects they produce at different doses. For investors, it matters because these studies determine safe and effective dosing, identify risks, shape clinical trial outcomes and regulatory decisions, and therefore influence a drug’s chances of approval, market size and commercial value; think of it as the science that maps a drug’s real-world performance.

risk-based quality management (rbqm) medical

"Xcellerate®, Fortrea’s platform for Risk-Based Quality Management (RBQM), Central Monitoring"

Risk-based quality management (RBQM) is a regulatory approach that focuses monitoring and oversight efforts on the most important risks to patient safety and data reliability in clinical development and manufacturing. For investors, RBQM signals that a company is prioritizing regulatory compliance and efficient use of resources—like a mechanic checking the brakes before routine parts—reducing the chance of costly errors, trial delays, or regulatory setbacks.

central monitoring medical

"Xcellerate®, Fortrea’s platform for Risk-Based Quality Management (RBQM), Central Monitoring and Oversight"

A centralized process for watching and analyzing data from multiple clinical trial sites remotely, like a control room using dashboards and alerts instead of relying only on local site visits. It helps detect safety issues, data problems, or protocol deviations faster and more consistently, which can reduce costs, speed up development, and lower regulatory and operational risk—factors investors use to judge a trial’s likelihood of timely success.

eTMF medical

"automating key steps, from pre-award to final eTMF."

An eTMF (electronic Trial Master File) is a secure digital filing cabinet that holds the key documents and records generated during a clinical trial, such as protocols, consent forms, monitoring notes and regulatory correspondence. For investors, a well‑organized eTMF matters because it shows a sponsor can document and defend its trial conduct to regulators and auditors; poor or missing records can delay approvals, create costly setbacks or reduce the value of a drug program.

software-as-a service (saas) technical

"with select components available as software-as-a service (SaaS)."

A delivery model where companies provide software over the internet and customers pay to use it, typically through recurring subscriptions rather than buying a one-time license. For investors this matters because subscription-based sales are like rental income—more predictable and often scalable, which can support steady cash flow and faster growth, but it also makes metrics such as customer retention and churn central to assessing long-term value.

ai-powered technical

"Persona driven, AI-powered solutions automate workflows and streamline oversight"

"AI-powered" describes technology that uses artificial intelligence to perform tasks, make decisions, or analyze information automatically. It’s similar to having a highly skilled assistant that can learn from data, recognize patterns, and improve over time, helping to make processes faster and more accurate. For investors, this means better insights and more efficient operations, potentially leading to smarter investment choices.

machine learning technical

"With embedded AI and machine learning, Xcellerate® can analyze complex patterns"

Machine learning is a set of computer programs that learn patterns from large amounts of data and improve their predictions or decisions over time, like a recipe that gets better each time it’s adjusted based on taste tests. For investors it matters because these systems can speed up analysis, spot trends or risks humans might miss, automate routine work, and potentially create competitive advantages or cost savings that affect a company’s performance.

View in glossary

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

AI-enhanced suite of solutions features new and improved technology to empower efficiency, confidence and quality

Highlights:

• Designed to transform clinical trial operations for sponsors, sites and study teams
• Persona driven, AI-powered solutions automate workflows and streamline oversight to help improve trial speed, predictability and quality
• Builds on Fortrea’s flagship platform Xcellerate^® to deliver near-real-time, role-based insights
  

DURHAM, N.C., April 07, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global clinical research organization (CRO), today unveiled Fortrea Intelligent Technology™(FIT), a suite of innovative technology solutions designed to transform clinical trial operations.

By integrating persona-driven, AI-powered solutions that automate workflows, streamline oversight and elevate productivity, FIT helps enable sponsors, investigator sites and Fortrea project teams to deliver trials faster, with greater predictability, agility and quality.

An Innovative, Intelligent Suite of Clinical Solutions
FIT encompasses major enhancements to familiar Fortrea offerings, including the award-winning Xcellerate^® platform, along with newly launched solutions designed to integrate all processes within the trial ecosystem.

The suite boasts applications for biopharma and biotech customers across clinical pharmacology, clinical development and medical device development, and it can be deployed in both full service and functional service models, with select components available as software-as-a service (SaaS).

FIT solutions are arranged into three pillars:

• Lifecycle: Deliver Trials Faster with Confidence
  Solutions that help sponsors and sites progress clinical trials throughout each step of the clinical development journey. They help accelerate clinical trials by automating key steps, from pre-award to final eTMF.
  
  
• Foresight: Turn Data into Actionable Insights
  Solutions that transform data into foresight, helping enable faster decision-making and proactive risk mitigation. They provide clarity, trend analysis and risk mitigation through intuitive dashboards that empower confident, near-real-time decisions and simplified oversight.
  
  
• Companion: Empowering Study Teams to Work Smarter
  Persona-driven, AI-powered solutions that support more productive and efficient clinical trial operations. They help streamline study delivery, help boost productivity and enable collaboration.
  

“We are at a remarkable moment in time, where the evolution of clinical trials is converging with unprecedented advancements in technology. Fortrea Intelligent Technology sits at this nexus,” said Chief Information Officer Alejandro Martinez Galindo. “Built on decades of industry experience and direct sponsor and investigator site input, FIT delivers human-centered solutions that enable sponsors and sites to conduct trials more efficiently, with greater confidence and lower risk.”

Xcellerate^® Anchors the Intelligent Suite
Xcellerate^®, Fortrea’s platform for Risk-Based Quality Management (RBQM), Central Monitoring and Oversight, is the foundation of the FIT offering.

Recent enhancements deliver a modern, intuitive experience that integrates data across the trial ecosystem to provide near-real-time, role-based insights. With embedded AI and machine learning, Xcellerate^® can analyze complex patterns, generate predictive signals and initiate automated workflows, reducing manual effort and enabling teams to focus on the critical human judgment required for successful clinical research.

“We expect these Xcellerate^® enhancements and the broader FIT platform will be game changers for our study teams and our clients,” said Chief Operating Officer and President, Clinical Development Mark Morais. “Incorporating the responsible and ethical use of AI, these technologies enable a stronger research ecosystem and the ability to respond more quickly to what the data are telling us—all of which can make the difference in getting life-changing treatments to patients faster and more efficiently.”

Fortrea continues to expand the Fortrea Intelligent Technology portfolio, with additional solutions planned for future release.

About Fortrea
Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team, operating across approximately 100 countries, is scaled to deliver focused, agile solutions to clients globally. Learn more about how Fortrea is streamlining drug development at Fortrea.com and follow us on LinkedIn, X and Bluesky.

Fortrea Contacts:
Jennifer Minx (Media) – 919-410-4195, media@fortrea.com
Kate Dillon (Media) – 646-818-9115, kdillon@prosek.com
Tracy Krumme (Investors) – 984-385-6707, Tracy.Krumme@fortrea.com

FAQ

What is Fortrea Intelligent Technology (FIT) announced by Fortrea (FTRE) on April 7, 2026?

FIT is an AI-enhanced suite designed to automate clinical trial workflows and improve oversight across trial teams. According to Fortrea, FIT integrates persona-driven solutions and Xcellerate® to deliver near-real-time, role-based insights across clinical pharmacology, development and device programs.

How does Fortrea say Xcellerate® supports the new FIT suite for FTRE customers?

Xcellerate® anchors FIT by providing risk-based quality management, central monitoring and integrated data analytics. According to Fortrea, enhancements add embedded AI and machine learning to generate predictive signals and initiate automated workflows for faster decision-making.

What are the three pillars of Fortrea Intelligent Technology (FTRE) and their purposes?

The three pillars are Lifecycle, Foresight and Companion, each addressing distinct needs in trials. According to Fortrea, Lifecycle accelerates trial steps, Foresight turns data into actionable insights, and Companion empowers study teams with persona-driven automation and collaboration tools.

Which trial types and deployment models does Fortrea say FIT supports for FTRE clients?

FIT supports clinical pharmacology, clinical development and medical device programs across full-service and functional service models. According to Fortrea, select FIT components are also available as software-as-a-service (SaaS) for flexible deployment and integration.

What operational benefits does Fortrea claim FIT will deliver for sponsors and sites?

Fortrea states FIT aims to speed trials, improve predictability and raise quality while reducing manual effort. According to Fortrea, persona-driven AI automates workflows and provides near-real-time oversight to help teams focus on critical human judgment.

Will Fortrea (FTRE) expand FIT after the April 7, 2026 launch?

Fortrea indicated the FIT portfolio will continue to expand with additional solutions planned for future release. According to Fortrea, ongoing enhancements will broaden capabilities built on Xcellerate® and further integrate trial ecosystem processes.